Darwin Global Management, Ltd. Quant / Systematic

CIK: 0001839209 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 14, 2024

Total Value ($000): $509,484 (100.0% shares, 0.0% debt)

Holdings (8)

— AMBRX BIOPHARMA INC 46.6%

Value ($000) $237,646 Shares 16,688,636 Est. Cost $14.24 Unrealized —

TGTX TG THERAPEUTICS INC 13.6%

Value ($000) $69,116 Shares 4,046,598 Est. Cost $11.62 Unrealized 0.0%

MLTX MOONLAKE IMMUNOTHERAPEUTICS 12.3%

Value ($000) $62,763 Shares 1,039,289 Est. Cost $51.54 Unrealized 0.0%

CYTK CYTOKINETICS INC 9.8%

Value ($000) $50,094 Shares 600,000 Est. Cost $36.21 Unrealized 0.0%

KROS KEROS THERAPEUTICS INC 8.3%

Value ($000) $42,163 Shares 1,060,427 Est. Cost $31.36 Unrealized 0.0%

PCVX VAXCYTE INC 7.1%

Value ($000) $36,421 Shares 579,959 Est. Cost $51.94 Unrealized 0.0%

— SPRINGWORKS THERAPEUTICS INC 1.4%

Value ($000) $7,035 Shares 192,734 Est. Cost $36.50 Unrealized —

NUVL NUVALENT INC 0.8%

Value ($000) $4,246 Shares 57,698 Est. Cost $61.88 Unrealized 0.0%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	AMBRX BIOPHARMA INC	16,688,636	$237,646	46.6%	$14.24	—	COM	641871108
TGTX	TG THERAPEUTICS INC	4,046,598	$69,116	13.6%	$11.62	0.0%	COM	88322Q108
MLTX	MOONLAKE IMMUNOTHERAPEUTICS	1,039,289	$62,763	12.3%	$51.54	0.0%	CLASS A ORD	61559X104
CYTK	CYTOKINETICS INC	600,000	$50,094	9.8%	$36.21	0.0%	COM NEW	23282W605
KROS	KEROS THERAPEUTICS INC	1,060,427	$42,163	8.3%	$31.36	0.0%	COM	492327101
PCVX	VAXCYTE INC	579,959	$36,421	7.1%	$51.94	0.0%	COM	92243G108
—	SPRINGWORKS THERAPEUTICS INC	192,734	$7,035	1.4%	$36.50	—	COM	85205L107
NUVL	NUVALENT INC	57,698	$4,246	0.8%	$61.88	0.0%	COM	670703107